OMIG

In multiple divisions we investigate the of use molecular targeted tracers for optical imaging in the near-infrared spectrum.

Technology

We provide in-house development of GMP tracers and develop and test multiple imaging system.

Publications & news

Find our published research and read updates.

Patient

Ben jij patiënt en kom je binnenkort bij ons langs voor een voorlichting of een procedure?

Milestones

First in-human results

In 2011 our research group performed the first in-human fluorescence study concerning intraoperative staining of ovarian cancer.

First spectroscopy study

The TRACT-I was the first study that utilized NIR spectroscopy in rectal cancer patients using Bevacizumab-IRDye800CW.

First endoscopic study

In 2014 the first study started using systemic and topical administration of a fluorescence-labelled antibody against vascular endothelial growth factor (VEGF) utilizing a NIR infrared camera system.

First Head and Neck Cancer study

Start of ICON study; the first Head and Neck Cancer study at OMIG. The ICON study is a clinical trial for the intraoperative assessment of tumor margins during surgical treatment using cetuximab-IRDye800CW

Start of Thyroid TARGET study

The Thyroid Cancer Target study is a dual study. The first part started in 2018, using EMI-137 in targeting thyroid cancer. The second part started in 2021, utilizing Bevacizumab-IRDye800CW.

Start of first IBD study

The VISION study is the first study that focussed on IBD pathology. In this study Vedolizumab-800CW is utilized to identify inflamed gut mucosa using near-infrared fluorescence molecular endoscopy (NIR-FME), spectroscopy and confocal laser endomicroscopy (CLE).